Evaluating Intensive Insulin Therapy With Empagliflozin in Type 2 Diabetes: A Randomised Study
Abstract
Aims/introduction: Glucotoxicity exacerbates hyperglycemia by impairing insulin secretion and sensitivity, necessitating effective interventions. Although short-term intensive insulin therapy (SIIT) mitigates glucotoxicity, the effect of combining SIIT with sodium-glucose co-transporter 2 (SGLT2) inhibitors in hospitalised type 2 diabetes mellitus (T2DM) patients with severe hyperglycemia remains unclear. Herein, we aimed to evaluate the efficacy and safety of combining SGLT2 inhibitors with basal bolus therapy (BBT) for glycemic control in hospitalised patients with T2DM.
Materials and methods: In this randomised, open-label, single-centre trial, 35 eligible T2DM patients hospitalised for treating hyperglycemia were allocated to the BBT (n = 17) or BBT with empagliflozin (BBT + E) groups (n = 18). Patients were monitored for 7 days using flash glucose monitoring. The primary outcome was time-in-range (TIR, 70-180 mg/dL). The secondary outcomes included time-above-range (TAR), time-below-range (TBR), daily glucose levels, total daily insulin dose and ketone body concentration.
Results: The BBT + E group exhibited a significantly higher TIR from day 2, which exceeded 70% by day 5, with reduced TAR and insulin requirements. Blood glucose levels declined more rapidly in the BBT + E group, accompanied by a modest ketone elevation without severe ketoacidosis. The TBR increased marginally on day 7, primarily nocturnally; but no symptomatic hypoglycaemia occurred.
Conclusion: The…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 35 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.